<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02337140</url>
  </required_header>
  <id_info>
    <org_study_id>9357</org_study_id>
    <nct_id>NCT02337140</nct_id>
  </id_info>
  <brief_title>Indication of Permanent Cardiac Parcing After Tanscatheter Aortic Valve Implantation</brief_title>
  <acronym>TAVISTIM</acronym>
  <official_title>Indication of Permanent Cardiac Parcing After Tanscatheter Aortic Valve Implantation : Contribution of Electrophysioly Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since 2002, transcatheter aortic valve implantation (TAVI) has resulted in a dramatic change&#xD;
      in the prognosis of patients with aortic valve stenosis illegible to surgery. However, this&#xD;
      intervention may induce heavy conduction disorder due to the proximity of the aortic annulus&#xD;
      and the conduction pathways. So far, there is no clear recommandation for clinical management&#xD;
      of conduction disorder after TAVI. Standard criterion cannot be applied due to the multiple&#xD;
      comorbidity factors observed in these patients. As described in conventional aortic valve&#xD;
      surgery, a degree of inflammation and ischemia of the conduction pathways may be involved in&#xD;
      the first days. This is the reason underlying the systematic implantation of epicardial&#xD;
      electrodes. Such temporary back-up pacing is not possible in TAVI patients.&#xD;
&#xD;
      The primary end-point of this study is to confirm that standard criterion for pacing are&#xD;
      reliable in post-TAVI conduction disorders and to analyze the contribution of a systematic&#xD;
      electrophysiological study (EPS).&#xD;
&#xD;
      In TAVI patients, indications for pacing were persistent high-degree atrioventricular block&#xD;
      (AVB) or bundle branch block appearance associated to HV interval longer than 70ms, 24 hours&#xD;
      after the procedure.&#xD;
&#xD;
      After a two-month follow-up, clinical and ECG evaluation and 24-hour holter monitoring will&#xD;
      be realized in patients without pacemaker and compared to data obtained from the devices in&#xD;
      pacemaker-implanted patients (% of ventricular pacing &gt; 1% ; presence of more than 1 AVB&#xD;
      episod).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusions will take place from August 2014 to February 2015. We plan to include 165&#xD;
      consecutive patients with TAVI through a femoral approach.&#xD;
&#xD;
      At the inclusion, clinical baseline and electrocardiographic data will be collected. During&#xD;
      the procedure, baseline ECG data as well as conduction disorders will be recorded. An EP&#xD;
      study will be performed (measure of AH and HV intervals) before and after TAVI. Aortic&#xD;
      surface area, transvalvular mean gradient, presence of periprothetic leak and LV ejection&#xD;
      fraction will be determined by echocardiography within the first 24 hours.&#xD;
&#xD;
      After the procedure, a 24-hour ECG monitoring will be done in ICU. A pacemaker will be&#xD;
      implanted in case of persistent severe conduction disorders at 24 hours post-TAVI . All&#xD;
      patients will be implanted with SORIN Group KORA DR devices to benefit from the AAI-SafeR&#xD;
      mode and the AVB episodes automated analysis. All implanted pacemakers will be settled with&#xD;
      identical parameters to allow appropriate patient data analysis (AAI-SafeR for sinus rhythm&#xD;
      patients and VVIR in chronic atrial fibrillation patients).&#xD;
&#xD;
      In patients with 24-hour persistence of bundle branch block onset after TAVI, a repeated EPS&#xD;
      with HV recording will be performed. If HV interval is &gt; 70ms, a pacemaker will be implanted&#xD;
      and the patient will be added to the pacemaker-implanted patients. In the absence of&#xD;
      persistent conduction disorder 24h after the procedure, no specific supervision will be done.&#xD;
&#xD;
      All patients will have a 2-month follow up. At this time, clinical, ECG and echocardiographic&#xD;
      data will be collected. Additional 24-hour Holter ECG monitoring will be performed in&#xD;
      non-implanted patients and additional device control will be performed in implanted patients.&#xD;
      Pacemaker implantation will be confirmed if there is more than 1% of ventricular pacing or at&#xD;
      least one DDD mode switch.&#xD;
&#xD;
      In non-implanted patients, the non-indication for pacing was confirmed in the absence of&#xD;
      clinical event and 24-hour Holter ECG recording abnormality.&#xD;
&#xD;
      The secondary endpoint of the study is to define a posteriori risk factors for pacemaker&#xD;
      implantation after TAVI included in the liste hereafter:&#xD;
&#xD;
        -  Clinical data: age, drug-induced bradycardia, hypertension, ischemic cardiomyopathy,&#xD;
           creatinin clearance, troponin value.&#xD;
&#xD;
        -  Electrocardiographic data: QRS duration, PR interval, preexisting bundle branch block or&#xD;
           AV block, QRS axis, sinus rhythm&#xD;
&#xD;
        -  Echocardiographic data : aortic surface area, LV ejection fraction, aortic&#xD;
           annulus/prothesis ratio, aortic annulus/balloon diameter ratio&#xD;
&#xD;
        -  Electrophysiological data : HV interval before and after TAVI&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to confirm appropriate pacing indication in patients with conduction disorders after TAVI</measure>
    <time_frame>2 months</time_frame>
    <description>Pacemaker implantation will be confirmed if there is more than 1% of ventricular pacing or at least one DDD mode switch in the memories.&#xD;
In non-implanted patients, the non-indication for pacing was confirmed in the absence of clinical event and 24-hour Holter ECG recording abnormality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measures electrocardiographic characteristics before and after implantation</measure>
    <time_frame>2 months</time_frame>
    <description>QRS width (milliseconds), space PR (milliseconds), presence of conduction disorders (atrioventricular block, block right or left branch), axis (degrees), sinus rhythm (yes / no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures echographic characteristics</measure>
    <time_frame>2 months</time_frame>
    <description>LVEF (in%), aortic valve area (cm2 / m2), aortic regurgitation (grade I / IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of bioprosthesis</measure>
    <time_frame>2 months</time_frame>
    <description>CoreValve, Edwards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positioning bioprosthesis</measure>
    <time_frame>2 months</time_frame>
    <description>high or low relative to the ring plane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameter of the implanted bioprosthesis and ratio with the surface of the patient's aortic valve</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Taking bradycardia preoperative treatment</measure>
    <time_frame>2 months</time_frame>
    <description>yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiological data</measure>
    <time_frame>2 months</time_frame>
    <description>HV interval measurement before and after the intervention (ms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameter ratio of pre-dilation balloon used during the procedure compared to the patient's valve area</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical characteristics</measure>
    <time_frame>2 months</time_frame>
    <description>ischemic heart disease history (specify bypass or angioplasty), cardiovascular risk factors (hypertension, diabetes, obesity, smoking ...), patient age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological characteristics</measure>
    <time_frame>2 months</time_frame>
    <description>creatinine before surgery, troponin after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Pacemaker</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient who have been implanted with a pacemaker after TAVI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Pacemaker</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient who have not been implanted with a pacemaker after TAVI</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacemaker SORIN Group KORA DR</intervention_name>
    <arm_group_label>Pacemaker</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transcatheter aortic valve implantation (TAVI)</intervention_name>
    <arm_group_label>No Pacemaker</arm_group_label>
    <arm_group_label>Pacemaker</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient undergoing TAVI through femoral approach&#xD;
&#xD;
          -  age &gt; 50 years&#xD;
&#xD;
          -  informed and written consent&#xD;
&#xD;
          -  patient with social security system&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  patient with previous pacemaker or ICD&#xD;
&#xD;
          -  patient under guardianship or curatorship&#xD;
&#xD;
          -  patient protected by law&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>THOMANN SARAH, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>August 11, 2014</study_first_submitted>
  <study_first_submitted_qc>January 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>complete AV-block</keyword>
  <keyword>HV-interval</keyword>
  <keyword>permanent pacemaker</keyword>
  <keyword>valve implantation</keyword>
  <keyword>severe</keyword>
  <keyword>conduction</keyword>
  <keyword>disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

